ArticleDiabetology & metabolic syndrome2025
Prognostic value of atherogenic index of plasma on the all-cause and causes-specific mortality among patients with metabolic dysfunction-associated steatotic liver disease.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between the atherogenic index of plasma and metabolic-associated/nonalcoholic fatty liver disease: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe atherogenic index of plasma (AIP) has been proposed as a potential predictor of prognosis for atherosclerosis and cardiovascular disease (CVD). However, its prognostic value in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.
methodsThis study included 4,062 participants with MASLD from the Third National Health and Nutrition Examination Survey (NHANES III). Kaplan-Meier curves, the Cox proportional hazards regression model, and restricted cubic splines (RCS) were used to assess the associations between the AIP and both all-cause and cause-specific mortality in patients with MASLD. Additionally, subgroup analyses and interaction test were conducted.
resultsDuring a median follow-up of 311 months, a total of 1821 (44.83%) all-cause deaths, 606 (14.92%) CVD deaths and 313 (7.71%) diabetes deaths occurred. After adjusting for potential confounding factors, the hazard ratios (HR) for the highest tertile (AIP ≥ 0.30) compared to the lowest tertile (AIP < 0.01) were 1.41 (95% confidence interval [CI]: 1.17-1.68; P < 0.001) for all-cause mortality, 1.49 (95% CI: 1.07-2.09; P = 0.019) for CVD mortality, and 2.27 (95% CI: 1.28-4.01; P = 0.005) for diabetes mortality. Furthermore, subgroup analyses revealed that the highest tertile of AIP was associated with an increased risk of CVD mortality in MASLD patients with diabetes (HR = 2.46; 95% CI: 1.46-4.13; P < 0.001) or obesity/overweight (HR = 2.36; 95% CI: 1.41-3.95; P = 0.001).
conclusionsThe elevated AIP is independently associated with all-cause mortality, as well as CVD and diabetes mortality in patients with MASLD. AIP can be used as a prognostic indicator for patients with MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.